Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.

@article{Lawrentschuk2011EfficacyOA,
  title={Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.},
  author={Nathan L Lawrentschuk and Kimberly R Fernandes and David Bell and Jack Barkin and Neil Fleshner},
  journal={The Journal of urology},
  year={2011},
  volume={185 3},
  pages={848-54}
}
PURPOSE Men with castrate resistant prostate cancer have limited treatment options. Although luteinizing hormone-releasing hormone agonists are in the same class, they are slightly different in their pharmacology. We determined whether rechallenging patients with prostate cancer, who were receiving a luteinizing hormone-releasing hormone analogue but had progression, with a different luteinizing hormone-releasing hormone analogue (goserelin or leuprolide acetate) would result in a prostate… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Nonmetastatic Castration-Resistant Prostate Cancer

Korean journal of urology • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…